ストックスクリーナーアプリを入手
9.68
1.50%
0.18
Prothena Corp Plc (PRTA) 最新ニュース
Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepens - AD HOC NEWS
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
PRTAProthena Corp Plc Options - Finviz
Price to sales forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to revenue forward of Prothena Corporation plc – NASDAQ:PRTA - TradingView
Enterprise value to EBIT forward of Prothena Corporation plc – NASDAQ:PRTA - TradingView
Price to book forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to EBITDA forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to revenue forward of Prothena Corp. Plc – MUN:0PT - TradingView
Prothena Corp, Parkinson antibody program draws attention for the stock - AD HOC NEWS
Prothena Corp. Plc Actuals & Estimates (NASDAQ:PRTA) - TradingView
Prothena Corp. Plc Actuals & Estimates (DUS:0PT) - TradingView
Prothena Corp. Plc Actuals & Estimates (SWB:0PT) - TradingView
PRTA Forecast — Price Target — Prediction for 2027 - TradingView
0PT Forecast — Price Target — Prediction for 2027 - TradingView
Prothena Corporation PLC (PRTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prothena Corporation Plc (NASDAQ:PRTA) About To Shift From Loss To Profit - Moomoo
Prothena Corp plc strategy in focus, shares watched against biotech peers - AD HOC NEWS
Prothena Corporation PLC (PRTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prothena Corporation PLC (PRTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prothena Corporation PLC (PRTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (PRTA) for Rule-Based Strategy - Stock Traders Daily
(PRTA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
PRTA Q1 2026 Earnings: Surprise EPS Beat Driven by Milestone Revenue, Stock Edges HigherDownward Estimate Revision - The Legal Advocate
(PRTA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Penbrook Management LLC's Prothena Corp PLC(PRTA) Holding History - GuruFocus
Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay - Stock Titan
Rubric Capital and David Rosen disclose 9.29% stake in Prothena (PRTA) - Stock Titan
Prothena Corp plc stock (IE00B91XRN20): Biotech investor focus amid pipeline updates - AD HOC NEWS
Number of shareholders of Prothena Corp. Plc – DUS:0PT - TradingView
PRTA Stock Price, Quote & Chart | PROTHENA CORP PLC (NASDAQ:PRTA) - ChartMill
William Scully reports 10.27% stake in PROTHENA (NASDAQ: PRTA) - Stock Titan
Prothena Corp. Down Over 9%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Prothena (PRTA) Heavy US$244 Million Annual Loss Tests Bullish Profitability Narratives - Sahm
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment - Yahoo Finance
Prothena (PRTA) Highlights Progress in Parkinson's Research and Collaborations - GuruFocus
Citizens raises Prothena stock price target on milestone payment By Investing.com - Investing.com UK
Prothena (PRTA) Revises 2026 Cash Outlook and Operating Expenses - GuruFocus
Prothena (NASDAQ:PRTA) Smashes Q1 Estimates on $50 Million Milestone Payment, Shares Steady - ChartMill
Prothena: Q1 Earnings Snapshot - marketscreener.com
Milestone revenue lifts Prothena (NASDAQ: PRTA) cash and pipeline - Stock Titan
Prothena (NASDAQ: PRTA) posts $32.7M Q1 profit and lifts 2026 cash outlook - Stock Titan
A $50M Novo milestone reshaped Prothena’s 2026 cash outlook - Stock Titan
Tranche Update on Prothena Corporation plc's Equity Buyback Plan announced on February 27, 2026. - marketscreener.com
Prothena to Report First Quarter 2026 Financial Results on May 7 - ChartMill
3 Growth Companies Insiders Are Eager To Hold - Sahm
Prothena (NASDAQ:PRTA) Shares Up 5.9%Time to Buy? - MarketBeat
FDA Fast Track granted to Phase 3 drug for ATTR-CM - Stock Titan
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe
Prothena authorizes up to $100 million share repurchase plan - MSN
PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan
Price vs Value Analysis | Prothena Corporation posts 29.8% EPS beat with narrower loss - Cổng thông tin điện tử tỉnh Lào Cai
PRTA (Prothena Corporation plc Ordinary Shares) rises 3.61 percent after Q4 2025 EPS outpaces analyst consensus estimates.AI Powered Stock Picks - Xã Châu Thành
Liquidity Mapping Around (PRTA) Price Events - Stock Traders Daily
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Prothena (NASDAQ:PRTA) Share Price Passes Above 200-Day Moving AverageTime to Sell? - MarketBeat
Prothena Corp plc stock (IE00B91XRN20): Why does its biotech pipeline matter more now for investors? - AD HOC NEWS
Prothena FY25 Earnings Review: Partnered Programs Advance Toward Milestones as Wholly-Owned Assets Pivot - AlphaStreet
2.26%
2.86%
大文字化:
|
ボリューム (24 時間):